Skip to main content

Table 3 Allred scores of Ki67 biomarker immunohistochemistry results in ER-β-negative and ER-β-positive cases

From: Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness–a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer

Ki67 Anastrozole (A) Placebo (P) Tamoxifen (T)
  Pre-treatment Post-treatment Pre-treatment Post-treatment Pre-treatment Post-treatment
ER- β-negative      
Mean ± SD 4.2 ± 1.9 3.5 ± 2.8 2.3 ± 1.4 2.2 ± 1.7 4.6 ± 1.9 3.4 ± 2.7
Median (minimum–maximum) 4 (2–8) 2 (0–8) 2 (0–4) 2 (0–5) 4 (2–7) 3 (0–7)
Total (n) 11 11 12 12 5 5
ER- β-positive      
Mean ± SD 4.5 ± 2 3.2 ± 2.1* 3.6 ± 1.8 4 ± 1.6 3.8 ± 1.8 2.9 ± 2.1**
Median (minimum–maximum) 4 (0–7) 2 (0–7) 4 (0–6) 4 (2–6) 4 (0–6) 3 (0–7)
Total (n) 13 13 16 16 18 18
  1. SD: standard deviation.
  2. ER-β-negative: ANOVA with repeated measures: group (p = 0.071), treatment (p = 0.084) and group × treatment (p = 0.446).
  3. ER-β-positive: ANOVA with repeated measures: group (p = 0.726), treatment (p = 0.036) and group × treatment (p = 0.032).
  4. Bonferroni multiple comparison test for ER-β-positive analysis: group A (pre- × post-treatment: p = 0.014*), group P (pre- × post-treatment: p = 0.113) and group T (pre- × post-treatment: p = 0.046**).